CoChat

ANATOMICAL MEASURES AS PREDICTORS OF VISUAL OUTCOMES IN RANIBIZUMAB-TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Brown, David M., Tuomi, Lisa, Shapiro, Howard · 2013 · Retina
Cited by 74

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

In Brief Purpose: To investigate if anatomical characteristics of eyes undergoing ranibizumab therapy were predictive of best-corrected visual acuity (BCVA) outcomes over 2 years. Methods: Post hoc analyses of patients with age-related macular degeneration from PIER studies, defined by fundus fluorescein angiography, quantitative optical coherence tomography (OCT), and qualitative OCT, were performed to determine if associations with BCVA outcomes could be found. Results: Ranibizumab-treated subgroups defined by baseline fundus fluorescein angiography lesion size and composition did not differ in BCVA outcomes at Month 24 (P = 0.13–1.0). Inactivity on fundus fluorescein angiography at Month 3 was associated with a 12-letter gain by Month 12 (P < 0.01), whereas inactivity on Month 3 qualitative OCT was not (P > 0.05). Qualitative OCT inactivity at Month 5 and separately at Month 8 was associated with greater BCVA gains by Month 24 (7.1 and 9.5 letters, respectively; P ≤ 0.045) versus eyes with OCT activity. Conclusion: When assessed separately, eyes with qualitative OCT (Months 5 and 8) or fundus fluorescein angiography (Months 3 and 5) inactivity maintained vision gain from baseline at Month 24, while those with leakage not only lost initial vision gains achieved by intraocular ranibizumab but also had net vision losses from baseline at Month 24. The PIER infrequent dosing regimen likely exaggerated and accelerated the deleterious effects of retinal fluid on BCVA, and it is not known whether these findings are applicable to treatment regimens that use more frequent monitoring and dosing of ranibizumab. When assessed separately, eyes with qualitative optical coherence tomography (Months 5 and 8) or fundus fluorescein angiography (Months 3 and 5) inactivity maintained vision gain from baseline at Month 24 while those with leakage not only lost initial vision gains achieved by intraocular ranibizumab, but also had net vision losses from baseline at Month 24. The PIER infrequent dosing regimen likely exaggerated and accelerated the deleterious effects of retinal fluid on best-corrected visual acuity and it is not known whether these findings are applicable to treatment regimens that use more frequent monitoring and dosing of ranibizumab.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/iae.0b013e318263cedf

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 74

Metadata

Authors
Brown, D. M., Tuomi, L., & Shapiro, H.
Venue
Retina
Published
2013-01
Volume
33
Issue
1
Pages
23-34
ISSN
0275-004X (ISSN-L)
OpenAlex
W2026557323
Cited by
74
References
5
FWCI
5.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: ANATOMICAL MEASURES AS PREDICTORS OF VISUAL OUTCOMES IN RANIBIZUMAB-TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. https://app.cochat.ai/papers/10.1097/iae.0b013e318263cedf
The paper
Brown, D. M., Tuomi, L., & Shapiro, H. (2013). ANATOMICAL MEASURES AS PREDICTORS OF VISUAL OUTCOMES IN RANIBIZUMAB-TREATED EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. https://doi.org/10.1097/iae.0b013e318263cedf

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.